ALKERMES, INC. for ALKERMES, INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Maintain Medicare's Six Protected Classes status for depression and schizophrenia
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Pharmacy PHA
H.R. 4299, Improving Regulatory Transparency for New Medical Therapies Act DEA regulatory transparency in controlled substances scheduling process DEA regulatory transparency in issuing research licenses and quotas
| Lobbyist | Covered position, as disclosed |
|---|---|
| PETER NORMAN | — |
Alcohol and Drug Abuse ALC
Advance the use of FDA-approved medicines to treat addiction in criminal justice settings H.R.3465/S.1690, The Second Chance Act of 2013 - the use of FDA-approved medicines in criminal justice settings S.1675, Recidivism Reduction and Public Safety Act of 2013 - the use of FDA-approved medicines in criminal justice settings
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Law Enforcement/Crime/Criminal Justice LAW
Ensure access to medications in various crimial justice settings
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.